H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.

Wilson explains how Pfizer's decision to withdraw Oxbryta from global markets could affect the sickle cell community.

Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

AbbVie has been reporting an earnings decline because its former lead drug, Humira, lost patent-protected market exclusivity ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Robert F. Kennedy, Jr. has been antivax for two decades. His fellow travelers are not happy about his leaving out vaccines in ...

Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.

Mr Lowe said that while he was not opposed to vaccines, his life had been destroyed. The Public Health Agency (PHA) said the ...